Atlas Trials

A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer

Clinical trial NCT05621434 · UNKNOWN

Trial details

NCT number
NCT05621434
Sponsor
Fujian Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-positive Recurrent/Metastatic Breast Cancer
Start date
2022-12-10
Primary completion
2024-12-10
Enrollment
63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.